The Natural Alkaloid Bousigonine D Improves Insulin Sensitivity and Glucose Homeostasis through Concurrent PI3K/AKT and AMPK Activation

Abstract Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder driven primarily by insulin resistance and disordered glucose and lipid metabolism, which poses a substantial global health and economic burden. This study was designed to evaluate the therapeutic potential of Bousigonine D (BSG-D), a monoterpenoid indole alkaloid from Bousigonia mekongensis, and to elucidate its underlying mechanisms in ameliorating insulin resistance and associated metabolic dysregulation in T2DM. Using a combination of in vivo (high-fat diet plus streptozotocin-induced diabetic mouse model) and in vitro (HepG2 insulin-resistant cell model) experimental approaches, along with biochemical assays, histopathological examination, and analysis of protein expression, we found that administration of BSG-D induced a rapid reduction in blood glucose levels within 6 hours in diabetic mice and improved systemic glucose homeostasis, as demonstrated by enhanced performance in both oral glucose tolerance and insulin tolerance tests. BSG-D treatment also effectively modulated serum lipid profiles, lowering total cholesterol and free fatty acids levels. Histopathological examination revealed that BSG-D ameliorated pancreatic and hepatic damage, characterized by improved cellular architecture and diminished inflammatory infiltration. Consistent with these effects in vivo, as shown by decreased serum insulin levels and a reduced HOMA-IR index, BSG-D restored glucose consumption in insulin-resistant HepG2 cells. These findings highlight the multifaceted therapeutic potential of BSG-D in T2DM management, supporting its promise as a novel therapeutic agent. Future studies should prioritize clinical validation and incorporate multi-omics strategies to further elucidate the mechanisms of action of BSG-D and advance its application in T2DM treatment.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-16
DOI
https://doi.org/10.21203/rs.3.rs-11243720/v1
Primary Topic
Natural Antidiabetic Agents Studies
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

The Natural Alkaloid Bousigonine D Improves Insulin Sensitivity and Glucose Homeostasis through Concurrent PI3K/AKT and AMPK Activation

Qianhui Ning, Zhiwei Wang, Yanting Lu, Hedi Wang et al.
3 links
Research Square
Natural Antidiabetic Agents Studies
preprint

The Natural Alkaloid Bousigonine D Improves Insulin Sensitivity and Glucose Homeostasis through Concurrent PI3K/AKT and AMPK Activation

Qianhui Ning, Zhiwei Wang, Yanting Lu, Hedi Wang, Qiang Chen
preprint en

Abstract

Abstract Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder driven primarily by insulin resistance and disordered glucose and lipid metabolism, which poses a substantial global health and economic burden. This study was designed to evaluate the therapeutic potential of Bousigonine D (BSG-D), a monoterpenoid indole alkaloid from Bousigonia mekongensis, and to elucidate its underlying mechanisms in ameliorating insulin resistance and associated metabolic dysregulation in T2DM. Using a combination of in vivo (high-fat diet plus streptozotocin-induced diabetic mouse model) and in vitro (HepG2 insulin-resistant cell model) experimental approaches, along with biochemical assays, histopathological examination, and analysis of protein expression, we found that administration of BSG-D induced a rapid reduction in blood glucose levels within 6 hours in diabetic mice and improved systemic glucose homeostasis, as demonstrated by enhanced performance in both oral glucose tolerance and insulin tolerance tests. BSG-D treatment also effectively modulated serum lipid profiles, lowering total cholesterol and free fatty acids levels. Histopathological examination revealed that BSG-D ameliorated pancreatic and hepatic damage, characterized by improved cellular architecture and diminished inflammatory infiltration. Consistent with these effects in vivo, as shown by decreased serum insulin levels and a reduced HOMA-IR index, BSG-D restored glucose consumption in insulin-resistant HepG2 cells. These findings highlight the multifaceted therapeutic potential of BSG-D in T2DM management, supporting its promise as a novel therapeutic agent. Future studies should prioritize clinical validation and incorporate multi-omics strategies to further elucidate the mechanisms of action of BSG-D and advance its application in T2DM treatment.

Research Square
Shandong University of Traditional Chinese Medicine (CN), Shandong First Medical University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Shandong Province
Good health and well-being
Natural Antidiabetic Agents Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon